SAN DIEGO, Calif., March 7, 2002 (PRIMEZONE) --
Saturday, March 16, 2002:
William T. Abraham, M.D., FACP, FACC &
Clyde W. Yancy, M.D., FACC
CardioDynamics (Nasdaq:CDIC), the innovator and global leader of Impedance Cardiography (ICG) technology, today announced that an Impedance Cardiography Continuing Medical Education Symposium, sponsored by the University of Minnesota, will be held in Atlanta on Saturday, March 16, 2002 at 6 p.m. The ICG Symposium will be chaired by William T. Abraham, M.D., FACP, FACC, Chief of Cardiovascular Medicine and Co-Director of Gill Heart Institute, University of Kentucky College of Medicine and includes a presentation by Clyde W. Yancy, M.D., FACC, Medical Director of Heart Failure/Heart Transplantation, at the University of Texas Southwestern Medical Center & St. Paul University Hospital, Dallas, Texas.
Commenting on the Symposium, William T. Abraham, M.D., FACP, FACC, stated, "Clinicians are coming full-circle and returning to viewing heart failure as a hemodynamic (blood flow) disease. It is the clinicians' responsibility to become familiar with ICG technology, its applications, and its proven role in clinical decision-making and treatment."
WHERE: Omni Hotel at CNN Center, Ballroom III
100 CNN Center, Atlanta, Georgia
AGENDA: 6:00 - 6:30 p.m.-Registration and Hors D'oeuvres
6:30 - 6:45 PM - Heart failure as a Hemodynamic
Disease Review of Literature and Clinical Practice,
William T. Abraham, MD
6:45 - 7:05 PM - Noninvasive Hemodynamic Monitoring:
Impedance Cardiography (ICG) Technology, Overview,
Validity, and Current Clinical Studies, Clyde W. Yancy,
MD
7:05 - 7:30 PM - Clinical Case Study Review: Role of ICG in
Clinical Decision Making, Panel Discussion with Audience
Feedback, Closing Comments
There is no fee for the program for ACC attendees and guests. To pre-register, please contact Jennifer Conklin at 800-778-4825 (U.S.); 858-535-0202, Ext. 1063 / jconklin@cdic.com.
About CardioDynamics:
CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator and global leader of breakthrough medical technology called Impedance Cardiography (ICG). The Company's primary products, the BioZ(r) Systems, are being used by leading physicians around the world to help battle the number one killer of men and women - cardiovascular disease. Partners include GE Medical Systems Information Technologies, Spacelabs Medical Systems, and Vasomedical. The worldwide market potential for BioZ products is estimated to be $5 billion and an additional $800 million in recurring annual revenue for disposables. For additional information or to request an investor package, please refer to the company's Web site at www.cdic.com.
Forward-Looking (Safe Harbor) Statement:
Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 2000 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.